Unique Safer Medicines

Sweden, Sweden

Short Summary

Inorbit discovers drugs for the treatment of NASH. Its lead project, the FXR agonist IOT022, shows great in vivo efficacy and drug like properties. It is ready for IND characterisation studies, starting Q1 2019, preparing it for testing in man.

Highlights

  • IOT022 shows perfect in vivo efficacy, and drug like ADME properties
  • Ready for IND enabling studies
  • Provisional Patent Application filed.
  • Led by a team of well seasoned entrepreneurial drug hunters.
  • Excellent opportunity for high return on low investment.
Please note: Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. This information has not been approved as a financial promotion, and you must carry out your own due diligence.

Overview

Target
€2,000,000
Minimum
€50,000
Investment Raised
€100,000
Previous Rounds €450,000
Stage Pre-Startup/R&D
Investor Role Any

Want to pitch on Angel Investment Network?

It’s easy to create a pitch using our online form. Your pitch can be in front of our 195,407 investors before you know it.

Create New Account
Already have an account?

Similar Projects

Global Pro
16% raised

Concussion detection kit

Finland

A great number of mild traumatic brain injuries (mTBI) and concussions occur each year. Many of them, however, remain undiagnosed. Medicortex Finland has discovered a solution that gives a quick answer to whether or not a brain injury has occurred.

€ 500,000

Target

€ 5,000

Min per Investor

Global Pro
30% raised

Dubai Healthbiz crowdfund

UAE

Apple Clinic; estd 2007; JCI accredited Healthcare business running 4 Medical Centres in the UAE with 120k+ registered patients, connections with 27 leading insurance co; looking to expand in UAE's healthcare market valued at $20.03b (2020).

€ 4,300,000

Target

€ 87

Min per Investor

Featured
6% raised

Trillum Eye Care Pre-IPO

South East, USA

Join this international health care group expand clinics in North America. Convertible Note pays 10% interest which converts into Stock pre-IPO. Company is targeting an IPO in the US.

€ 1,300,000

Target

€ 4,300

Min per Investor

load one similar proposal